Artikel ; Online: CD28-Kostimulation und Checkpointblockade in T-Zellen.
2020 Band 61, Heft 7, Seite(n) 652–659
Abstract: Background: The induction of protective T cell responses requires two signals: Signal 1 is generated by activation of the T cell receptor (TCR) and signal 2 results from ligation of the CD28 molecule. Costimulation of the TCR and CD28 is necessary, as ... ...
Titelübersetzung | CD28 costimulation and checkpoint inhibition in T cells. |
---|---|
Abstract | Background: The induction of protective T cell responses requires two signals: Signal 1 is generated by activation of the T cell receptor (TCR) and signal 2 results from ligation of the CD28 molecule. Costimulation of the TCR and CD28 is necessary, as the TCR is very good at discriminating between endogenous and foreign structures (antigens), but not all foreign antigens (such as food antigens) are dangerous to the body. A strong CD28 signal, thus, indicates to the T cell that there is indeed a threat and that an immune response is urgently required. However, to avoid autoimmunity and excessive immune responses, further regulatory circuits, provided by immune checkpoints, are necessary. Objectives: To provide an introduction to immunoregulation mediated by checkpoint molecules. Materials and methods: Review of basic science papers and reports on clinical studies. Results: The most prominent and best characterized checkpoint molecules, cytotoxic T lymphocyte-associated protein‑4 (CTLA-4) and programmed cell death‑1 (PD-1), both physiologically dampen CD28-mediated costimulation. Pathologically, malignancies exploit the immunoregulatory function of checkpoint molecules by, for example, expressing ligands for PD‑1 on the cell surface, thus, avoiding being attacked by T cells. Our understanding of these negative feedback regulations has led to the development of checkpoint inhibitors, which have already become part of routine clinical care of cancer patients. Conclusions: Due to the clinical success of checkpoint inhibitors, the concept of cancer immunotherapy has received a massive boost and hopes are high that many more clinical advancements in cancer therapy can be achieved with novel forms of immunotherapy. |
Mesh-Begriff(e) | Antigens, CD ; CD28 Antigens/physiology ; CTLA-4 Antigen ; Humans ; Immunotherapy ; T-Lymphocytes/immunology |
Chemische Substanzen | Antigens, CD ; CD28 Antigens ; CTLA-4 Antigen |
Sprache | Deutsch |
Erscheinungsdatum | 2020-05-28 |
Erscheinungsland | Germany |
Dokumenttyp | Journal Article ; Review |
ZDB-ID | 2913-0 |
ISSN | 1432-1289 ; 0020-9554 |
ISSN (online) | 1432-1289 |
ISSN | 0020-9554 |
DOI | 10.1007/s00108-020-00813-0 |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Volltext online
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
Ua VI Zs.380: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.